European Biosimilar Updates

On February 13, 2026, STADA and Bio-Thera announced that they have received European Marketing Authorization for GOTENFIA®, a golimumab biosimilar to Johnson & Johnson’s SIMPONI®. GOTENFIA® is a human monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), a key driver of inflammation in multiple autoimmune conditions. ... By: Goodwin